Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
AB

NASDAQ · ABUS

Arbutus Biopharma Corporation

Healthcare · Biotechnology

$4.21

Down-$0.07 (-1.64%)

Updated Oct 31, 2026, 12:52 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
896.23M
P/E ratio
-21.14
Dividend yield
0.00%
52-week range
$4.01 – $5.45
Volume
2.53M
Avg. volume
1.58M

Price performance · ABUS

ABUS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ABUS closed at $4.21 after 21 trading sessions, down 5.39% for the selected period.

Last close
$4.21
Period change
-5.39%
Period low
$4.11
Period high
$4.67
Daily close
View OHLC price history
ABUS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$4.28$4.3045$4.1413$4.212.53M
Oct 29, 2026$4.34$4.38$4.23$4.281.21M
Oct 28, 2026$4.24$4.33$4.22$4.321.34M
Oct 27, 2026$4.20$4.295$4.18$4.291.62M
Oct 26, 2026$4.22$4.26$4.18$4.201.41M
Oct 23, 2026$4.17$4.22$4.1211$4.202.03M
Oct 22, 2026$4.22$4.37$4.175$4.212.46M
Oct 21, 2026$4.32$4.35$4.17$4.183.03M
Oct 20, 2026$4.24$4.365$4.22$4.332.11M
Oct 19, 2026$4.24$4.28$4.15$4.231.96M
Oct 16, 2026$4.29$4.29$4.18$4.224.54M
Oct 15, 2026$4.23$4.30$4.215$4.292.28M
Oct 14, 2026$4.07$4.25$4.05$4.192.43M
Oct 13, 2026$4.13$4.155$4.05$4.113.48M
Oct 12, 2026$4.20$4.23$4.12$4.152.34M
Oct 9, 2026$4.17$4.27$4.13$4.223.15M
Oct 8, 2026$4.22$4.30$4.05$4.184.85M
Oct 7, 2026$4.46$4.48$4.28$4.294.79M
Oct 6, 2026$4.67$4.67$4.43$4.488.26M
Oct 5, 2026$4.45$4.80$4.41$4.676.18M
Oct 2, 2026$4.55$4.68$4.375$4.458.99M

Latest ABUS news

The latest Smart Investors Daily articles mentioning ABUS.

Stock researchCompany · Overview

ABUS research

Overview

Company profile and research snapshot.

Company profile

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.50
Implied upside
—
Analysts
—
ABUS recent ratings
DateFirmRatingTarget
Nov 14, 2025Chardan CapitalBuy—
Aug 11, 2025Chardan CapitalBuy—
Mar 28, 2025Chardan CapitalBuy—
Jan 21, 2025HC Wainwright & Co.Buy—
Nov 20, 2024Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (“FDA”) that the clinical hold on the Investigational New Drug (“IND”) application for AB-101 has been removed and that the Company may engage in additional clinical development for AB-101 in the United States. Ar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By